Pre-Made Bifikafusp Alfa Biosimilar, Fusion Protein targeting FN/FN1 fused with human IL2 (interleukin 2, IL-2) Pr21-153 (100%) (1:1), noncovalent dimer: Recombinant therapeutic protein targeting CIG/ED-B/FINCZ/GFND/GFND2/LETS/MSF/SMDCF for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Bifikafusp Alfa Biosimilar, Fusion Protein targeting FN/FN1 fused with human IL2 (interleukin 2, IL-2) Pr21-153 (100%) (1:1), noncovalent dimer: Recombinant therapeutic protein targeting CIG/ED-B/FINCZ/GFND/GFND2/LETS/MSF/SMDCF is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Bifikafusp alfa is a fusion protein of pro-inflammatory IL-2 and IL19 human mAb fragment (scFv domain) that binds the tumor microenvironment expressed fibronectin extradomain B (EDB). Incorporation of the IL19 binding fragment targets the drug to the tumor, improving selective site accumulation and tumor killing and at the same time reducing the effective dose required to achieve a meaningful response, and reducing the otherwise dose-limiting toxicities associated with high-dose IL-2 administration that would be required to produce the same killing effect.
| Products Name (INN Index) | Pre-Made Bifikafusp Alfa Biosimilar, Fusion Protein targeting FN/FN1 fused with human IL2 (interleukin 2, IL-2) Pr21-153 (100%) (1:1), noncovalent dimer: Recombinant therapeutic protein targeting CIG |
|---|---|
| INN Name | bifikafusp alfa |
| Target | FN |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | scFv – heavy – kappa |
| VD LC | scFv – heavy – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Philogen (Sovicille Italy) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | FN |
| Package |
